The Potential of Cannabidiol for Acute Respiratory Distress Syndrome in COVID-19-Reference-Cited by-全球学者库

The Potential of Cannabidiol for Acute Respiratory Distress Syndrome in COVID-19

Published:2023-08 Issue:29 Volume:29 Page:2291-2296
ISSN:1381-6128
Container-title:Current Pharmaceutical Design
language:en
Short-container-title:CPD

Author:

Azimi Saeid¹,Saghafi Fatemeh²,Mohammadi Mohammad Hossein³,Moghimi Mohammad Hossein⁴,Akhavan Seyed Ali⁴,Khataminia Masoud⁵,Shirvani Maria⁶,Sohrevardi Seyed Mojtaba²,Jamialahmadi Tannaz⁷,Sahebnasagh Adeleh⁸,Sahebkar Amirhossein⁷⁹

Affiliation:

1. Student Research Committee, Faculty of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran

2. Department of Clinical Pharmacy, Faculty of Pharmacy and Pharmaceutical Sciences Research Center, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

3. Shahid Sadoughi University of Medical Sciences, Yazd, Iran

4. Student Research Committee, Faculty of Pharmacy, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

5. Student Research Committee, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran

6. Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

7. Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

8. Department of Internal Medicine, Clinical Research Center, North Khorasan University of Medical Sciences, Bojnurd, Iran

9. Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Abstract: COVID-19 disease manifests itself in a wide range of signs and symptoms, beginning with mild symptoms, such as fever, cough, and dyspnea, progressing to acute respiratory distress syndrome (ARDS) and death in some cases. The cytokine storm, or an excess of cytokines released locally, is assumed to be the primary cause of ARDS and mortality in COVID-19 patients. To enhance the survival rate of COVID-19 patients, early management of the cytokine storm with immunomodulators is crucial. Although the effectiveness of some immunosuppressants, such as corticosteroids and tocilizumab, has been studied in clinical trials, the administration of these drugs should be exercised cautiously. Cannabidiol (CBD) is a non-psychotropic phytocannabinoid from Cannabis sativa extracts with anti-inflammatory properties. This review is intended to discuss the possible utility of CBD for the management of COVID-19 patients, particularly those with ARDS.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,Pharmacology

Reference66 articles.

1. Segreto R.; Deigin Y.; McCairn K.; Sousa A.; Sirotkin D.; Sirotkin K.; Should we discount the laboratory origin of COVID-19? Springer 2021.

2. Jayaweera M.; Perera H.; Gunawardana B.; Manatunge J.; Transmission of COVID-19 virus by droplets and aerosols: A critical review on the unresolved dichotomy. Environ Res 2020,188,109819

3. Vetter P.; Vu D.L.; L’Huillier A.G.; Schibler M.; Kaiser L.; Jacquerioz F.; Clinical features of COVID-19. BMJ 2020,369,m1470

4. Wang F.; Huang S.; Gao R.; Zhou Y.; Lai C.; Li Z.; Xian W.; Qian X.; Li Z.; Huang Y.; Tang Q.; Liu P.; Chen R.; Liu R.; Li X.; Tong X.; Zhou X.; Bai Y.; Duan G.; Zhang T.; Xu X.; Wang J.; Yang H.; Liu S.; He Q.; Jin X.; Liu L.; Initial whole-genome sequencing and analysis of the host genetic contribution to COVID-19 severity and susceptibility. Cell Discov 2020,6(1),83

5. Booth A.; Reed A.B.; Ponzo S.; Yassaee A.; Aral M.; Plans D.; Labrique A.; Mohan D.; Population risk factors for severe disease and mortality in COVID-19: A global systematic review and meta-analysis. PLoS One 2021,16(3),e0247461